

From: Riemenschneider, Marion on behalf of Office, Vas Narasimhan (Gen)
Sent: Tuesday, September 06, 2016 1:42 PM
Subject: Important Organizational Announcement



Important Organizational Announcement

Dear Colleagues,

I am pleased to announce that **Dave Morris** has been appointed *Venture Partner* in the *Novartis Venture Fund (NVF)*, effective September 15, 2016. In his new role, Dave will report to Reinhard Ambros, Head Novartis Venture Fund. Dave will be responsible for identifying and developing new companies focused on emerging biomedical and technological insights.

He will take an active leadership role as a board member in developing companies in the NVF portfolio and as such will also interact between both the NIBR and Development organizations and the NVF portfolio companies. Dave will be a strong addition to the NVF team to create products for patient benefit and financial returns for entrepreneurs and investors.

Dave's contributions to our organization and to changing the practice of medicine are very significant. He joined Novartis 7 years ago, playing a critical role as Development Head of

the Respiratory and Primary Care franchises, where he ran several programs, and introduced multiple therapies including Onbrez/Arcapta, Seebri, Ultibro/Utibron, TOBI Podhaler, QAW039, LIK066, among many others. Over the last year, he has successfully built the Clinical Operations Analytics and Regions (COAR) function.

In the last few months, Dave has also successfully led the initial design and implementation of the new Global Development Operations (GDO) function, ensuring a smooth transition to Badhri Srinivasan.

Please join me in thanking Dave for his outstanding contributions to Novartis Development, congratulating him on his new position and wishing him much success in his new role at Novartis.

Best regards,

Vas

